Archives
-
Proteoform-Specific Drug Targeting in Native Membranes
2026-09-09
Lutomski et al. developed a native top-down mass spectrometry workflow that releases membrane proteins and signaling complexes directly from retinal disc membranes while preserving proteoform-dependent interactions. The study reveals how lipid modifications shape rhodopsin and G-protein behavior and shows that sildenafil and vardenafil display differential off-target reactivity with retinal PDE6.
-
PPM-18 for iNOS and NF-κB Research
2026-09-08
PPM-18 provides a practical way to separate NF-κB-driven iNOS expression from direct nitric oxide synthase catalysis in inflammation and sepsis research. This workflow-focused guide covers DMSO handling, LPS challenge design, orthogonal readouts, and assay troubleshooting while translating insights from a bone-remodeling study into defensible experimental choices.
-
Neurotensin for GPCR Trafficking Studies
2026-09-07
Build a controlled Neurotensin workflow for NTR1 signaling, receptor recycling, and miR-133α measurements in gastrointestinal cell models. This guide combines practical peptide handling with an evidence-aware strategy for managing analytical interference and improving assay reproducibility.
-
BFH772 (VEGFR2 inhibitor): Practical Lab Guide
2026-09-07
BFH772 is a selective VEGFR2 inhibitor for studies that require controlled perturbation of VEGFR2-dependent signaling and angiogenesis rather than broad kinase inhibition. Its water insolubility and dependence on organic solvents make it unsuitable for workflows requiring direct aqueous formulation, while its reported 3 nM VEGFR2 kinase IC50 supports use as a reference compound in biochemical and cellular assay development.
-
3X (DYKDDDDK) Peptide in Cell Assays
2026-09-05
Learn how 3X (DYKDDDDK) Peptide, SKU A6001, supports identity, recovery, and exposure controls in recombinant-protein workflows connected to cell viability, proliferation, and cytotoxicity assays. This scenario-based guide covers compatibility, storage, metal-sensitive detection, interpretation, and practical vendor selection.
-
Resiniferatoxin: TRPV1 Precision Beyond Analgesia
2026-09-05
Resiniferatoxin is more than an ultra-potent TRPV1 agonist: it is a context-sensitive tool for separating calcium signaling, sensory-neuron desensitization, and durable functional silencing. This thought-leadership perspective connects RTX assay design with translational pain research while examining an important immune-oncology caveat from metastatic breast cancer models.
-
Microlipophagy and Radioresistance in SCLC
2026-09-04
A 2026 study identifies microlipophagy-driven lipid droplet remodeling as a metabolic adaptation associated with radioresistant small-cell lung cancer. By combining imaging, lipid measurements, pharmacological autophagy inhibition, and transcriptomics, the authors show that disrupting this pathway can restore radiation sensitivity in resistant cells.
-
Dehydroabietic acid: Design Better PPAR Assays
2026-09-04
Dehydroabietic acid can help researchers separate receptor-driven transcription from substrate-driven metabolic effects. This article presents a time-resolved assay framework for studying dual PPAR-α/γ agonism, lipid metabolism regulation, and metabolic disorder research.
-
Firefly Luciferase mRNA: Reliable Assay Workflows
2026-09-03
Learn how EZ Cap™ Firefly Luciferase mRNA (5-moUTP), SKU R1013, can address inconsistent reporter expression, delivery variability, and interpretation challenges in cell viability and cytotoxicity workflows. This scenario-based guide connects product specifications with practical controls and recent evidence on small-scale mRNA delivery systems.
-
YM-155 Hydrochloride: Reading Cancer Cell Responses
2026-09-02
YM-155 hydrochloride is a selective survivin inhibitor whose apparent activity depends on how researchers measure cancer-cell response. This guide applies Schwartz’s viability framework to assay design, model selection, and interpretation of apoptosis inhibitor research.
-
Cistanche Nanovesicles Protect Sertoli Cells
2026-09-02
This study identifies Cistanche deserticola exosome-like nanovesicles (CDELNs) as a plant-derived intervention for cyclophosphamide-induced testicular injury. Its central mechanistic finding is that vesicle-delivered miR159b-3p suppresses P21, restores CDK1 phosphorylation, and alleviates cell-cycle arrest in Sertoli cells, with implications for male reproductive injury research.
-
DOPE: From Membrane Fusion to Translational Insight
2026-09-02
1,2-Dioleoyl-sn-glycero-3-PE (DOPE) is more than a helper lipid for nucleic acid delivery. Its membrane-fusion behavior offers a practical formulation advantage, while lipidomics research in Magnaporthe oryzae shows why phospholipid composition should also be treated as a mechanistic variable in translational studies.
-
SGI-1027 DNA Methyltransferase Inhibitor Workflows
2026-09-01
SGI-1027 supports mechanistic DNA methylation inhibition, tumor suppressor gene reactivation, and cancer-cell death studies in one adaptable workflow. Its value extends beyond conventional methylation assays by enabling investigation of vacuolation, lysosomal membrane permeability, and combination activity with everolimus in renal cancer models.
-
10074-G5: Applied c-Myc Inhibitor Workflows
2026-08-31
10074-G5 is a practical c-Myc inhibitor for connecting MYC/Max signaling with viability, apoptosis, cell cycle, and epithelial-to-mesenchymal transition assays. This workflow uses the compound to test the MYC/TERT/NFκB axis described in esophageal adenocarcinoma while separating evidence-backed observations from recommended optimization conditions.
-
Sodium Ascorbate in Cancer Research
2026-08-31
Sodium Ascorbate is a mineral salt of ascorbic acid investigated as a redox-active research reagent. Product information reports intracellular ROS induction, cancer cell proliferation inhibition, and preclinical activity in glioblastoma models, but these findings do not establish clinical efficacy or validate use as a therapeutic supplement.